PET cell tracking using 18 F-FLT is not limited by local reuptake of free radiotracer

Mark G. Macaskill; Adriana S. Tavares; Junxi Wu; Christophe Lucatelli; Joanne C. Mountford; Andrew H. Baker; David E. Newby; Patrick W.F. Hadoke

doi:10.1038/srep44233

PET cell tracking using 18 F-FLT is not limited by local reuptake of free radiotracer

Mark G. Macaskill^*, Adriana S. Tavares, Junxi Wu, Christophe Lucatelli, Joanne C. Mountford, Andrew H. Baker, David E. Newby, Patrick W.F. Hadoke

^*Corresponding author for this work

Biomedical Engineering

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

14 Downloads (Pure)

Abstract

Assessing the retention of cell therapies following implantation is vital and often achieved by labelling cells with 2′-[ 18 F]-fluoro-2′-deoxy-D-glucose (18 F-FDG). However, this approach is limited by local retention of cell-effluxed radiotracer. Here, in a preclinical model of critical limb ischemia, we assessed a novel method of cell tracking using 3′-deoxy-3′-L-[ 18 F]-fluorothymidine (18 F-FLT); a clinically available radiotracer which we hypothesise will result in minimal local radiotracer reuptake and allow a more accurate estimation of cell retention. Human endothelial cells (HUVECs) were incubated with 18 F-FDG or 18 F-FLT and cell characteristics were evaluated. Dynamic positron emission tomography (PET) images were acquired post-injection of free 18 F-FDG/ 18 F-FLT or 18 F-FDG/ 18 F-FLT-labelled HUVECs, following the surgical induction of mouse hind-limb ischemia. In vitro, radiotracer incorporation and efflux was similar with no effect on cell viability, function or proliferation under optimised conditions (5 MBq/mL, 60 min). Injection of free radiotracer demonstrated a faster clearance of 18 F-FLT from the injection site vs. 18 F-FDG (p ≤ 0.001), indicating local cellular uptake. Using 18 F-FLT-labelling, estimation of HUVEC retention within the engraftment site 4 hr post-administration was 24.5 ± 3.2%. PET cell tracking using 18 F-FLT labelling is an improved approach vs. 18 F-FDG as it is not susceptible to local host cell reuptake, resulting in a more accurate estimation of cell retention.

Original language	English
Article number	44233
Number of pages	10
Journal	Scientific Reports
Volume	7
DOIs	https://doi.org/10.1038/srep44233
Publication status	Published - 13 Mar 2017

Funding

This work was funded by the Medical Research Council (MR/K00719X/1), The University of Edinburgh British Heart Foundation Core (RE/13/3/30183), The University of Edinburgh British Heart Foundation Centre for Vascular Regeneration (RM/13/2/30158) and The University of Edinburgh School of Clinical Sciences Funding Challenge. DEN is funded by the British Heart Foundation (CH/09/002) and is the recipient of a Wellcome Trust Senior Investigator Award (WT103782AIA). AHB is funded by the British Heart Foundation Chair of Translational Cardiovascular Sciences. We would like to thank the radiochemistry team within the Edinburgh Clinical Research Imaging Centre, as well as Dr. Susan Champion, Dr. Sally Pimlott and their team at the Greater Glasgow and Clyde NHS PET Centre for their crucial work and efforts to supply the radiotracers used in this study.

Keywords

cell therapy
cardiovascular disease
positron emission tomography

Access to Document

10.1038/srep44233Licence: CC BY 4.0

MacAskill-etal-SR-2017-PET-cell-tracking-using-18-F-FLT-is-not-limitedFinal published version, 1.97 MBLicence: CC BY 4.0

Cite this

@article{b985bd7b7c6f4796b23d2aa65fc5ec7d,

title = "PET cell tracking using 18 F-FLT is not limited by local reuptake of free radiotracer",

abstract = "Assessing the retention of cell therapies following implantation is vital and often achieved by labelling cells with 2′-[ 18 F]-fluoro-2′-deoxy-D-glucose (18 F-FDG). However, this approach is limited by local retention of cell-effluxed radiotracer. Here, in a preclinical model of critical limb ischemia, we assessed a novel method of cell tracking using 3′-deoxy-3′-L-[ 18 F]-fluorothymidine (18 F-FLT); a clinically available radiotracer which we hypothesise will result in minimal local radiotracer reuptake and allow a more accurate estimation of cell retention. Human endothelial cells (HUVECs) were incubated with 18 F-FDG or 18 F-FLT and cell characteristics were evaluated. Dynamic positron emission tomography (PET) images were acquired post-injection of free 18 F-FDG/ 18 F-FLT or 18 F-FDG/ 18 F-FLT-labelled HUVECs, following the surgical induction of mouse hind-limb ischemia. In vitro, radiotracer incorporation and efflux was similar with no effect on cell viability, function or proliferation under optimised conditions (5 MBq/mL, 60 min). Injection of free radiotracer demonstrated a faster clearance of 18 F-FLT from the injection site vs. 18 F-FDG (p ≤ 0.001), indicating local cellular uptake. Using 18 F-FLT-labelling, estimation of HUVEC retention within the engraftment site 4 hr post-administration was 24.5 ± 3.2%. PET cell tracking using 18 F-FLT labelling is an improved approach vs. 18 F-FDG as it is not susceptible to local host cell reuptake, resulting in a more accurate estimation of cell retention.",

keywords = "cell therapy, cardiovascular disease, positron emission tomography",

author = "Macaskill, {Mark G.} and Tavares, {Adriana S.} and Junxi Wu and Christophe Lucatelli and Mountford, {Joanne C.} and Baker, {Andrew H.} and Newby, {David E.} and Hadoke, {Patrick W.F.}",

year = "2017",

month = mar,

day = "13",

doi = "10.1038/srep44233",

language = "English",

volume = "7",

journal = "Scientific Reports",

issn = "2045-2322",

}

TY - JOUR

T1 - PET cell tracking using 18 F-FLT is not limited by local reuptake of free radiotracer

AU - Macaskill, Mark G.

AU - Tavares, Adriana S.

AU - Wu, Junxi

AU - Lucatelli, Christophe

AU - Mountford, Joanne C.

AU - Baker, Andrew H.

AU - Newby, David E.

AU - Hadoke, Patrick W.F.

PY - 2017/3/13

Y1 - 2017/3/13

N2 - Assessing the retention of cell therapies following implantation is vital and often achieved by labelling cells with 2′-[ 18 F]-fluoro-2′-deoxy-D-glucose (18 F-FDG). However, this approach is limited by local retention of cell-effluxed radiotracer. Here, in a preclinical model of critical limb ischemia, we assessed a novel method of cell tracking using 3′-deoxy-3′-L-[ 18 F]-fluorothymidine (18 F-FLT); a clinically available radiotracer which we hypothesise will result in minimal local radiotracer reuptake and allow a more accurate estimation of cell retention. Human endothelial cells (HUVECs) were incubated with 18 F-FDG or 18 F-FLT and cell characteristics were evaluated. Dynamic positron emission tomography (PET) images were acquired post-injection of free 18 F-FDG/ 18 F-FLT or 18 F-FDG/ 18 F-FLT-labelled HUVECs, following the surgical induction of mouse hind-limb ischemia. In vitro, radiotracer incorporation and efflux was similar with no effect on cell viability, function or proliferation under optimised conditions (5 MBq/mL, 60 min). Injection of free radiotracer demonstrated a faster clearance of 18 F-FLT from the injection site vs. 18 F-FDG (p ≤ 0.001), indicating local cellular uptake. Using 18 F-FLT-labelling, estimation of HUVEC retention within the engraftment site 4 hr post-administration was 24.5 ± 3.2%. PET cell tracking using 18 F-FLT labelling is an improved approach vs. 18 F-FDG as it is not susceptible to local host cell reuptake, resulting in a more accurate estimation of cell retention.

AB - Assessing the retention of cell therapies following implantation is vital and often achieved by labelling cells with 2′-[ 18 F]-fluoro-2′-deoxy-D-glucose (18 F-FDG). However, this approach is limited by local retention of cell-effluxed radiotracer. Here, in a preclinical model of critical limb ischemia, we assessed a novel method of cell tracking using 3′-deoxy-3′-L-[ 18 F]-fluorothymidine (18 F-FLT); a clinically available radiotracer which we hypothesise will result in minimal local radiotracer reuptake and allow a more accurate estimation of cell retention. Human endothelial cells (HUVECs) were incubated with 18 F-FDG or 18 F-FLT and cell characteristics were evaluated. Dynamic positron emission tomography (PET) images were acquired post-injection of free 18 F-FDG/ 18 F-FLT or 18 F-FDG/ 18 F-FLT-labelled HUVECs, following the surgical induction of mouse hind-limb ischemia. In vitro, radiotracer incorporation and efflux was similar with no effect on cell viability, function or proliferation under optimised conditions (5 MBq/mL, 60 min). Injection of free radiotracer demonstrated a faster clearance of 18 F-FLT from the injection site vs. 18 F-FDG (p ≤ 0.001), indicating local cellular uptake. Using 18 F-FLT-labelling, estimation of HUVEC retention within the engraftment site 4 hr post-administration was 24.5 ± 3.2%. PET cell tracking using 18 F-FLT labelling is an improved approach vs. 18 F-FDG as it is not susceptible to local host cell reuptake, resulting in a more accurate estimation of cell retention.

KW - cell therapy

KW - cardiovascular disease

KW - positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=85015255581&partnerID=8YFLogxK

U2 - 10.1038/srep44233

DO - 10.1038/srep44233

M3 - Article

C2 - 28287126

AN - SCOPUS:85015255581

SN - 2045-2322

VL - 7

JO - Scientific Reports

JF - Scientific Reports

M1 - 44233

ER -

PET cell tracking using 18 F-FLT is not limited by local reuptake of free radiotracer

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Junxi Wu

Cite this

PET cell tracking using 18 F-FLT is not limited by local reuptake of free radiotracer

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Profiles

Junxi Wu

Cite this